AR083167A1 - Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas - Google Patents

Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas

Info

Publication number
AR083167A1
AR083167A1 ARP110103474A ARP110103474A AR083167A1 AR 083167 A1 AR083167 A1 AR 083167A1 AR P110103474 A ARP110103474 A AR P110103474A AR P110103474 A ARP110103474 A AR P110103474A AR 083167 A1 AR083167 A1 AR 083167A1
Authority
AR
Argentina
Prior art keywords
aryl
cycloalkyl
alkyl
heteroaryl
group
Prior art date
Application number
ARP110103474A
Other languages
English (en)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR083167A1 publication Critical patent/AR083167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Reivindicación 1: Compuesto sustituido de benzamida de la fórmula general (1), en donde, a representa 0 ó 1; t representa 1, 2 ó 3; b representa 0, 1 ó 2; c y d independientes entre sí, respectivamente, representan 0, 1 ó 2 con la condición de que el ciclo contenga 7 elementos del anillo como máximo; X representa N(R9a) o C(R9b)(H); D representa uno de los residuos de fórmula (D1) ó (D2); q representa 0 ó 1; s representa 0 ó 1; r representa 1, 2 ó 3; B representa C(=O), S(=O)2 o al grupo C(=O)-N(R10), en donde su átomo de nitrógeno está unido al residuo R1; Q1 y Q2, independientes entre sí, representan C, CH o N, respectivamente; R1 representa alquilo C1-9, arilo, heteroarilo, CH(arilo)2, cicloalquilo C3-8, heterociclilo, o bien, representar un arilo, heteroarilo, CH(arilo)2, cicloalquilo C3-8 o heterociclilo unido por un grupo alquilo C1-6, un grupo alquenilo C2-6 o un grupo alquinilo C2-6; R2 representa H, alquilo C1-6, cicloalquilo C3-8, heterociclilo, arilo, heteroarilo, o bien, representa un cicloalquilo C3-8, heterociclilo, arilo o heteroarilo unido por un grupo alquileno C1-6; R3 y R4 junto con el grupo -Q1-Q2- al que están unido, forman un ciclo, el cual puede ser anillado, no sustituido o sustituido en uno o varios, a modo de ejemplo, 1, 2 ó 3 de sus elementos del anillo de carbono con uno o más, a modo de ejemplo, 1, 2, 3 ó 4 sustituyentes independientes entre sí, seleccionados a partir del grupo formado por F, Cl, Br, I, CF3, alquilo C1-6, O-alquilo C1-6, OH, OCF3, SH, SCF3, arilo y heteroarilo y/o con al menos un, a modo de ejemplo, 1 ó 2, arilo o heteroarilo, en donde, el ciclo es saturado, en forma simple o múltiple, a modo de ejemplo, una o dos veces, no saturado o aromático, tiene de 4-, 5-, 6- ó 7- elementos, y que puede contener, en cada caso, uno o más, a modo de ejemplo, 1, 2 ó 3, heteroátomos o grupos de heteroátomos independientes entre sí, seleccionados a partir del grupo formado por N, NR11, O, S, S(=O) y S(=O)2; en donde el residuo R11 significa H, alquilo C1-6, C(=O)-R12, cicloalquilo C3-8, arilo, heteroarilo, o bien, significa un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquilo C1-3, y R12 significa alquilo C1-6, cicloalquilo C3-8, arilo, heteroarilo o un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3; R5 representa los sustituyentes 0, 1, 2, 3 ó 4, los cuales, independientes entre sí, seccionados a partir del grupo formado por F, Cl, CF3, OCF3, alquilo C1-6 y O-alquilo C1-6 y/o dos sustituyentes vecinos de R5 forman un arilo, heteroarilo o cicloalquilo C4-8 anillado y/o dos sustituyentes de R5 unidos a un átomo de carbono formen un carbociclo de 3, 4 ó 5 elementos, saturado, el cual es no sustituido o sustituido en uno o más de sus elementos del anillo de carbono con uno o más sustituyentes independientes entre sí, seleccionados a partir del grupo formado por F, CF3 y alquilo C1-6; R6 representa 0, 1, 2 ó 3 sustituyentes, los cuales, independientes entre sí, seleccionados a partir del grupo formado por F, Cl, Br, CF3, OCF3, OH, alquilo C1-6, cicloalquilo C3-8, O-alquilo C1-6, NO2, NH2, N(H)(alquilo C1-6) y N(alquilo C1-6)2 y/o los sustituyentes vecinos de R6 forman un arilo, heteroarilo o cicloalquilo C4-8 anillado; R7 representan H, alquilo C1-6, cicloalquilo C3-8, heterociclilo, arilo o heteroarilo, o bien, significa un cicloalquilo C3-8, heterociclilo, arilo o heteroarilo unido por un grupo alquileno C1-6; R8 representa 0, 1, 2, 3 ó 4 sustituyentes, los cuales, independientes entre sí, seleccionados a partir del grupo formado por CF3, alquilo C1-6 y cicloalquilo C3-8 y/o dos sustituyentes de R8 unidos a un átomo de carbono forman un grupo C(=O) o un carbociclo de 3, 4, 5, 6, 7 u 8 elementos, saturado, el cual es no sustituido o sustituido en uno o más de sus elementos del anillo de carbono con uno o más sustituyentes independientes entre sí, seleccionados a partir del grupo formado por F, CF3 y alquilo C1-6; R9a representa C(=O)-R13, S(=O)2-R13, C(=O)-N(R14)-R13, CHR15R16, cicloalquilo C3-8, heterociclilo, arilo o heteroarilo, o bien, significa, un CHR15R16, cicloalquilo C3-8, heterociclilo, arilo o heteroarilo unido por un grupo alquileno C1-6; R9b representa NR17R18, alquilo C1-6-NR17R18, O-alquileno C1-6-NR17R18, C(=O)-NR17R18, OR19, alquileno C1-6-OR19, alquileno C1-6-O-alquileno C1-6-OR19, alquilo C1-6, cicloalquilo C3-8, heterociclilo, arilo, heteroarilo, o bien, representa un cicloalquilo C3-8, heterociclilo, arilo o heteroarilo unido por un grupo alquileno C1-6; R10 representa H, alquilo C1-6, cicloalquilo C3-8, arilo, heteroarilo, o bien, representa cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3; R13 representa alquilo C1-6, arilo, heteroarilo, CH(arilo)2, cicloalquilo C3-8, heterociclilo, o bien, representa arilo, heteroarilo, cicloalquilo C3-8 o heterociclilo unido por un grupo alquileno C1-6, un grupo alquenilo C2-6 o un grupo alquinilo C2-6; R14 representa H, alquilo C1-6, cicloalquilo C3-8, arilo, heteroarilo, o bien, representa cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3; R15 y R16, independientes entre sí, cada uno, representan H, alquilo C1-4, cicloalquilo C3-8, arilo o heteroarilo, o R15 y R16 junto con los grupos CH a los cuales están asociados forman un ciclo, el cual es no sustituido o sustituido en uno o más, a modo de ejemplo, 1, 2 ó 3, de sus elementos del anillo de carbono con uno o más, a modo de ejemplo, 1, 2, 3 ó 4, sustituyentes independientes entre sí, seleccionados a partir del grupo formado por F, Cl, Br, I, CF3, alquilo C1-6, O-alquilo C1-6, OH, OCF3, SH, SCF3, NR20R21, arilo y heteroarilo, en donde, el ciclo saturado o no saturado en forma simple o múltiple, a modo de ejemplo, una o dos veces, pero no aromático, puede contener de 4-, 5-, 6- ó 7- elementos, y, en caso necesario, uno o más, a modo de ejemplo, 1, 2 ó 3, heteroátomos o grupos de heteroátomos independientes entre sí, seleccionados a partir del grupo formado por N, NR24, O, S, S(=O) y S(=O)2; en donde R24 significa H, alquilo C1-6, C(=O)-R25, cicloalquilo C3-8, arilo, heteroarilo o un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3, y R25 significa alquilo C1-6, cicloalquilo C3-8, arilo, heteroarilo o un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3; R17 y R18, independientes entre sí, cada uno, representan H, alquilo C1-6 o cicloalquilo C3-8, o R17 y R18, junto con el átomo de nitrógeno al cual están asociados, forman un heterociclo, el cual puede ser anillado, no sustituido o sustituido en uno o más, a modo de ejemplo, 1, 2 ó 3, de sus elementos del anillo de carbono con uno o más, a modo de ejemplo, 1, 2, 3 ó 4, sustituyentes independientes entre sí, seleccionados a partir del grupo formado por F, Cl, Br, I, CF3, alquilo C1-6, O-alquilo C1-6, OH, OCF3, SH, SCF3, NR20R21, arilo y heteroarilo y/o con al menos un, a modo de ejemplo, 1 ó 2, arilo o heteroarilo, en donde, el heterociclo es saturado o no saturado en forma simple o múltiple, a modo de ejemplo, una o dos veces, puede contener 4-, 5-, 6- ó 7- elementos, y, en caso necesario, uno o más, a modo de ejemplo, 1, 2 ó 3, heteroátomos o grupos de heteroátomos independientes entre sí, seleccionados a partir del grupo formado por N, NR22, O, S, S(=O) y S(=O)2; en donde R22 significa H, alquilo C1-6, -C(=O)-R23, cicloalquilo C3-8, arilo, heteroarilo, o bien, un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3, y R23 significa alquilo C1-6, cicloalquilo C3-8, arilo, heteroarilo, o bien, un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3; R19 representa H, alquilo C1-6, cicloalquilo C3-8, heterociclilo, arilo, heteroarilo o alquileno C2-6-NR17R18, o bien, un heterociclilo, cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-6; R20 y R21, independientes entre sí, cada uno, representa H, alquilo C1-6 o cicloalquilo C3-8, o R20 y R21, junto con el átomo de nitrógeno al cual están asociados, forman un heterociclo, el cual es no sustituido o sustituido en uno o más, a modo de ejemplo, 1, 2 ó 3, de sus elementos del anillo de carbono con uno o más, a modo de ejemplo, 1, 2, 3 ó 4 sustituyentes independientes entre sí, seleccionados a partir del grupo formado por F, Cl, Br, I, CF3, alquilo C1-6, O-alquilo C1-6, OH, OCF3, SH, SCF3, arilo y heteroarilo, en donde, el heterociclo es saturado o no saturado en forma simple o múltiple, a modo de ejemplo, una o dos veces, pero no aromático, de 4-, 5-, 6- ó 7- elementos, y, en caso necesario, puede contener uno o más, a modo de ejemplo, 1, 2, 3 ó 4, heteroátomos o grupos de heteroátomos independientes entre sí, seleccionados a partir del grupo formado por N, NR26, O, S, S(=O) y S(=O)2; en donde R26 significa H, alquilo C1-6, C(=O)-R27, cicloalquilo C3-8, arilo, heteroarilo, o bien, un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3, y R27 significa alquilo C1-6, cicloalquilo C3-8, arilo, heteroarilo, o bien, un cicloalquilo C3-8, arilo o heteroarilo unido por un grupo alquileno C1-3; en donde, los residuos antes mencionados alquilo C1-4, alquilo C1-6, alquileno C1-3, alquileno C1-6, alquileno C2-6, alquenileno C2-6, alquinileno C2-6, cicloalquilo C3-8, cicloalquilo C4-8, heterociclilo, arilo y, respectivamente, puede ser no sustituido o sustituido en forma simple o múltiple con residuos iguales o diferentes y los residuos señalados anteriormente, alquilo C1-4 alquilo C1-6, alquileno C1-3, alquileno C1-6, alquileno C2-6, alquenileno C2-6 y alquinileno C2-6, respectivamente ramificados o no ramificados; en la forma de un compuesto libre; del tautómero; del N-óxido; del racemato; del enantiómero, diastereómero, las mezclas de enantiómeros o diastereómeros, o bien, un enantiómero o diastereómero aislado; o en la forma de ácidos o bases fisiológicamente compatibles con sales.
ARP110103474A 2010-09-22 2011-09-23 Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas AR083167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10010200 2010-09-22

Publications (1)

Publication Number Publication Date
AR083167A1 true AR083167A1 (es) 2013-02-06

Family

ID=43770597

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103474A AR083167A1 (es) 2010-09-22 2011-09-23 Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas

Country Status (18)

Country Link
US (1) US8680159B2 (es)
EP (1) EP2619178A1 (es)
JP (1) JP2013540750A (es)
KR (1) KR20140000682A (es)
CN (1) CN103097354A (es)
AR (1) AR083167A1 (es)
AU (1) AU2011304666A1 (es)
BR (1) BR112013008667A2 (es)
CA (1) CA2811796A1 (es)
CL (1) CL2013000787A1 (es)
CO (1) CO6700838A2 (es)
EA (1) EA201300388A1 (es)
EC (1) ECSP13012519A (es)
IL (1) IL225350A0 (es)
MX (1) MX2013003309A (es)
PE (1) PE20131350A1 (es)
TW (1) TW201217312A (es)
WO (1) WO2012038081A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
US9034874B2 (en) * 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
BR112015025804B1 (pt) * 2013-04-12 2022-01-04 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida
WO2014186704A2 (en) * 2013-05-17 2014-11-20 N30 Pharmaceuticals, Inc. Novel compounds for the treatment of cystic fibrosis
ES2673876T3 (es) * 2013-12-19 2018-06-26 Eisai R&D Management Co., Ltd. Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor
CN105829293B (zh) * 2013-12-20 2018-11-09 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
MX2017005940A (es) 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
EP3215510B1 (en) 2014-11-06 2023-06-07 Bial-R&D Investments, S.A. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
JOP20190156B1 (ar) * 2016-12-23 2023-09-17 Bayer Pharma AG أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CN114933568A (zh) * 2022-05-24 2022-08-23 抚州润泰药业有限公司 一种4,6-二甲基-2-甲磺酰基嘧啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012077A1 (en) * 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
EP1656355B1 (en) * 2003-06-20 2008-03-12 Amgen Inc. Piperazine derivatives and methods of use
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP5136929B2 (ja) 2004-03-24 2013-02-06 アボット・ラボラトリーズ 三環式ピラゾール系キナーゼ阻害薬
JP2008537953A (ja) * 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
WO2007101007A2 (en) 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
JP5405303B2 (ja) 2006-09-29 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスルホンアミド誘導体
WO2008046573A1 (de) 2006-10-16 2008-04-24 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds

Also Published As

Publication number Publication date
CL2013000787A1 (es) 2013-09-23
CN103097354A (zh) 2013-05-08
TW201217312A (en) 2012-05-01
US20120071461A1 (en) 2012-03-22
MX2013003309A (es) 2013-04-29
PE20131350A1 (es) 2013-12-08
IL225350A0 (en) 2013-06-27
BR112013008667A2 (pt) 2016-06-21
US8680159B2 (en) 2014-03-25
EP2619178A1 (de) 2013-07-31
EA201300388A1 (ru) 2014-01-30
WO2012038081A1 (de) 2012-03-29
CA2811796A1 (en) 2012-03-29
AU2011304666A1 (en) 2013-05-02
ECSP13012519A (es) 2013-05-31
CO6700838A2 (es) 2013-06-28
JP2013540750A (ja) 2013-11-07
KR20140000682A (ko) 2014-01-03

Similar Documents

Publication Publication Date Title
AR083167A1 (es) Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR061647A1 (es) Inhibidores de cxcr2 y sus composiciones farmaceuticas
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
AR070910A1 (es) Derivados de sulfonamida sustituida
AR043427A1 (es) Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure